JP2011521654A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011521654A5 JP2011521654A5 JP2011512010A JP2011512010A JP2011521654A5 JP 2011521654 A5 JP2011521654 A5 JP 2011521654A5 JP 2011512010 A JP2011512010 A JP 2011512010A JP 2011512010 A JP2011512010 A JP 2011512010A JP 2011521654 A5 JP2011521654 A5 JP 2011521654A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- replicon
- replicon according
- delivery vehicle
- pestivirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000011859 microparticle Substances 0.000 claims description 5
- 241000710778 Pestivirus Species 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims 4
- 230000002458 infectious effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 108020004705 Codon Proteins 0.000 claims 3
- 101710172711 Structural protein Proteins 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 206010008631 Cholera Diseases 0.000 claims 1
- 101800000511 Non-structural protein 2 Proteins 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 4
- 239000002502 liposome Substances 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08010222A EP2130912A1 (en) | 2008-06-04 | 2008-06-04 | Pestivirus replicons providing an RNA-based viral vector system |
| EP08010222.1 | 2008-06-04 | ||
| PCT/EP2009/003892 WO2009146867A1 (en) | 2008-06-04 | 2009-05-30 | Pestivirus replicons providing an rna-based viral vector system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011521654A JP2011521654A (ja) | 2011-07-28 |
| JP2011521654A5 true JP2011521654A5 (enExample) | 2015-08-27 |
Family
ID=39967852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011512010A Pending JP2011521654A (ja) | 2008-06-04 | 2009-05-30 | Ｒｎａに基づくウイルスベクター系を提供するペスチウイルスレプリコン |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9249395B2 (enExample) |
| EP (2) | EP2130912A1 (enExample) |
| JP (1) | JP2011521654A (enExample) |
| CA (1) | CA2723999C (enExample) |
| WO (1) | WO2009146867A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2130912A1 (en) * | 2008-06-04 | 2009-12-09 | Institut für Viruskrankeiten und Immunprophylaxe | Pestivirus replicons providing an RNA-based viral vector system |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| US11291635B2 (en) | 2010-07-06 | 2022-04-05 | Glaxosmithkline Biological Sa | Virion-like delivery particles for self-replicating RNA molecules |
| AU2011276234B2 (en) | 2010-07-06 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Liposomes with lipids having an advantageous pKa- value for RNA delivery |
| SI2591114T1 (sl) | 2010-07-06 | 2016-10-28 | Glaxosmithkline Biologicals S.A. | Imunizacija velikih sesalcev z majhnimi odmerki RNA |
| ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
| WO2012031043A1 (en) * | 2010-08-31 | 2012-03-08 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| TR201908635T4 (tr) * | 2010-08-31 | 2019-07-22 | Glaxosmithkline Biologicals Sa | Protein kodlayıcı rna?nın lipozomal verilmesine uygun lipitler. |
| EP3520813B1 (en) | 2010-10-11 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| EP4014966A1 (en) * | 2011-07-06 | 2022-06-22 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| EP3854413A1 (en) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| US10022436B2 (en) | 2016-01-11 | 2018-07-17 | Verndari, Inc. | Microneedle compositions and methods of using same |
| US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| KR20190022711A (ko) | 2016-06-24 | 2019-03-06 | 론자 리미티드 | 가변 직경 생물 반응기 |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| WO2018129270A1 (en) | 2017-01-05 | 2018-07-12 | Fred Hutchinson Cancer Research Center | Systems and methods to improve vaccine efficacy |
| EP3740198A4 (en) | 2018-01-18 | 2023-08-09 | Fred Hutchinson Cancer Center | MODIFICATION OF INFLAMMATORY STATES OF IMMUNE CELLS IN VIVO BY MODULATION OF CELL ACTIVATION STATES |
| MX2022007905A (es) | 2019-12-31 | 2022-08-25 | Elixirgen Therapeutics Inc | Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos. |
| JP7798855B2 (ja) | 2020-07-16 | 2026-01-14 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子に使用するためのカチオン性脂質 |
| CA3242402A1 (en) | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| EP4474015A1 (en) | 2023-06-05 | 2024-12-11 | Veterna Srl | Noda-like rna-vaccine pharmacon and production and uses thereof |
| CN118955658A (zh) * | 2024-07-26 | 2024-11-15 | 华南农业大学 | 一种重组猪瘟病毒Npro蛋白、抗猪瘟病毒Npro蛋白的多克隆抗体及其制备方法与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6168942B1 (en) * | 1998-11-10 | 2001-01-02 | Pfizer Inc. | Attenuated forms of bovine viral diarrhea virus |
| EP1035205A1 (en) * | 1999-03-08 | 2000-09-13 | Stichting Dienst Landbouwkundig Onderzoek | Non-spreading pestivirus |
| US20030077251A1 (en) * | 2001-05-23 | 2003-04-24 | Nicolas Escriou | Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins |
| MXPA05001644A (es) * | 2002-08-13 | 2005-04-19 | Akzo Nobel Nv | Replicones de pestivirus que no expresan proteina c y/o e1, y particulas virales infecciosas que los contienen y pueden usarse en vacunas. |
| WO2004092386A2 (en) * | 2003-04-11 | 2004-10-28 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Inducing a t cell response with recombinant pestivirus replicons or recombinant pestivirus replicon-transfected dendritic cells |
| CA2605149A1 (en) * | 2005-04-26 | 2006-11-02 | Sandoz Ag | Production of recombinant proteins by autoproteolytic cleavage of a fusion protein |
| US20080305130A1 (en) * | 2005-12-07 | 2008-12-11 | Chichi Huang | Marked Bovine Viral Diarrhea Virus Vaccines |
| EP2130912A1 (en) * | 2008-06-04 | 2009-12-09 | Institut für Viruskrankeiten und Immunprophylaxe | Pestivirus replicons providing an RNA-based viral vector system |
-
2008
- 2008-06-04 EP EP08010222A patent/EP2130912A1/en not_active Withdrawn
-
2009
- 2009-05-30 EP EP09757250A patent/EP2297309A1/en active Pending
- 2009-05-30 CA CA2723999A patent/CA2723999C/en active Active
- 2009-05-30 JP JP2011512010A patent/JP2011521654A/ja active Pending
- 2009-05-30 WO PCT/EP2009/003892 patent/WO2009146867A1/en not_active Ceased
- 2009-05-30 US US12/995,874 patent/US9249395B2/en active Active
-
2015
- 2015-12-22 US US14/978,647 patent/US9670466B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hosseinkhani | Nanomaterials in advanced medicine | |
| Vinay et al. | Recent advances in application of nanoparticles in fish vaccine delivery | |
| Casmil et al. | The advent of clinical self-amplifying RNA vaccines | |
| JP2013533747A5 (enExample) | ||
| US10363226B2 (en) | Platelet membrane-coated drug delivery system | |
| Aliahmad et al. | Next generation self-replicating RNA vectors for vaccines and immunotherapies | |
| Abd Ellah et al. | Nanomedicine as a future therapeutic approach for Hepatitis C virus | |
| Tavakol et al. | The role of nanotechnology in current COVID-19 outbreak | |
| Liang et al. | Advances in antiviral material development | |
| CN1993113B (zh) | 包含磷酸钙纳米颗粒核心，生物分子和胆汁酸的颗粒，其生产方法，其治疗用途 | |
| CN108472354A (zh) | 呼吸道合胞病毒疫苗 | |
| Qu et al. | Macrophage‐biomimetic nanoplatform‐based therapy for inflammation‐associated diseases | |
| JP2010537989A5 (enExample) | ||
| JP2010017185A5 (enExample) | ||
| JP2013500720A5 (enExample) | ||
| JP2011525477A5 (enExample) | ||
| Hashemzadeh et al. | Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus | |
| Dash et al. | Advances in nanomedicine for the treatment of infectious diseases caused by viruses | |
| Yu et al. | The clinical progress and challenges of mRNA vaccines | |
| Xu et al. | New advances in nanomaterial‐based antiviral strategies | |
| Jampílek et al. | Nanoformulations: a valuable tool in the therapy of viral diseases attacking humans and animals | |
| Deng et al. | A review of nanomaterials in osteoarthritis treatment and immune modulation | |
| Anjum et al. | Co‐delivery of oncolytic virus and chemotherapeutic modality: Vincristine against prostate cancer treatment: A potent viro‐chemotherapeutic approach | |
| Wong et al. | COVID-19 Vaccine: Review of the Mechanism of Action of Different Types of Vaccine Li-Ann Wong*, Christina Gertrude Yap, Nowrozy Kamar Jahan, Naganathan Pillai. | |
| Debnath et al. | Potential application of bionanoparticles to treat severe acute respiratory syndrome coronavirus-2 infection |